◂ Announcements

Mar 31, 2020CONTRACT

Asarina Pharma chooses YpsoMate autoinjector for Sepranolone

Asarina Pharma has decided to use Ypsomed's YpsoMate autoinjector for its phase III study and commercial launch of Sepranolone, a treatment for pre-menstrual dysphoric disorder.

Status

Announced

ProductsYpsoMate autoinjectorSepranolone drug

CompaniesYpsomed supplier Asarina Pharma customer

Sectors#Medical Devices

“Asarina Pharma has decided to go with our user-friendly two-step autoinjector YpsoMate for its commercial launch of its drug Sepranolone.”ypsomed.com

1 source
ypsomed.comAsarina has chosen YpsoMate as the injection device for their drug Sepranolone - YpsomedMar 31, 2020

Summarized from public sources; check the original articles before acting on it.

More from Ypsomed

profile ▸

Apr 27, 2023NEW FACILITYChangzhou, China$38.0M
Ypsomed breaks ground on CHF 35M injection system plant in Changzhou, China
Ypsomed ypsomed.com
Aug 25, 2022EXPANSIONSchwerin, Germany
Ypsomed expands Schwerin plant with injection and infusion production lines
Ypsomed ypsomed.com
Aug 29, 2019EXPANSIONBurgdorf, Switzerland100 jobsops 29 Aug 2019
Ypsomed opens new building at headquarters in Burgdorf, Switzerland
Ypsomed ypsomed.com
Aug 22, 2019NEW FACILITYSchwerin, Mecklenburg-Vorpommern, Germany$90.0M150 jobsops 22 Aug 2019
Ypsomed starts production at new €81M medtech plant in Schwerin
Ypsomed welt.de ypsomed.com b2b-wirtschaft.de
Feb 15, 2019NEW FACILITYSchwerin, Germany, Germany$113.0M150 jobsops Jul 2019
Ypsomed to build €100M production facility in Schwerin, Germany
Ypsomed ie-group.com
Dec 7, 2018PRODUCT LAUNCHSwitzerland
Ypsomed's YpsoMate autoinjector enters market with Terumo and Mylan
Terumo customer Ypsomed supplier ypsomed.com

Loading…

Asarina Pharma chooses YpsoMate autoinjector for Sepranolone · Endata